Shopping Cart 0
Cart Subtotal
USD 0

Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Kuros Biosciences AG (KURN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company's lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Jul 24,2019: Kuros announces Gerhard Ries is stepping down as Board member

Apr 30,2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting

Apr 12,2019: Kuros Biosciences reports results for the full year 2018

Dec 17,2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track

Sep 05,2018: Kuros Biosciences announces results for first half 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Kuros Biosciences AG-Key Facts

Kuros Biosciences AG-Key Employees

Kuros Biosciences AG-Key Employee Biographies

Kuros Biosciences AG-Major Products and Services

Kuros Biosciences AG-History

Kuros Biosciences AG-Company Statement

Kuros Biosciences AG-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Kuros Biosciences AG-Business Description

R&D Overview

Kuros Biosciences AG-SWOT Analysis

SWOT Analysis-Overview

Kuros Biosciences AG-Strengths

Kuros Biosciences AG-Weaknesses

Kuros Biosciences AG-Opportunities

Kuros Biosciences AG-Threats

Kuros Biosciences AG-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Kuros Biosciences AG, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member

Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting

Apr 12, 2019: Kuros Biosciences reports results for the full year 2018

Dec 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track

Sep 05, 2018: Kuros Biosciences announces results for first half 2018

Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer

May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM

Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results

Mar 12, 2018: Kuros Biosciences obtains European patent covering osteoinductive materials

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Kuros Biosciences AG, Performance Chart (2014-2018)

Kuros Biosciences AG, Ratio Charts

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Kuros Biosciences AG, Key Facts

Kuros Biosciences AG, Key Employees

Kuros Biosciences AG, Key Employee Biographies

Kuros Biosciences AG, Major Products and Services

Kuros Biosciences AG, History

Kuros Biosciences AG, Subsidiaries

Kuros Biosciences AG, Key Competitors

Kuros Biosciences AG, Ratios based on current share price

Kuros Biosciences AG, Annual Ratios

Kuros Biosciences AG, Annual Ratios (Cont...1)

Kuros Biosciences AG, Interim Ratios

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Kuros Biosciences AG, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kuros Biosciences AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Medicopharm AG

Labatec Pharma SA

Genentech Inc

Geistlich Pharma AG

F. Hoffmann-La Roche Ltd

Aristo Pharma GmbH

Allergan Ltd

Kuros Biosciences AG (KURN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company's lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Jul 24,2019: Kuros announces Gerhard Ries is stepping down as Board member

Apr 30,2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting

Apr 12,2019: Kuros Biosciences reports results for the full year 2018

Dec 17,2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track

Sep 05,2018: Kuros Biosciences announces results for first half 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Kuros Biosciences AG-Key Facts

Kuros Biosciences AG-Key Employees

Kuros Biosciences AG-Key Employee Biographies

Kuros Biosciences AG-Major Products and Services

Kuros Biosciences AG-History

Kuros Biosciences AG-Company Statement

Kuros Biosciences AG-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Kuros Biosciences AG-Business Description

R&D Overview

Kuros Biosciences AG-SWOT Analysis

SWOT Analysis-Overview

Kuros Biosciences AG-Strengths

Kuros Biosciences AG-Weaknesses

Kuros Biosciences AG-Opportunities

Kuros Biosciences AG-Threats

Kuros Biosciences AG-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Kuros Biosciences AG, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member

Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting

Apr 12, 2019: Kuros Biosciences reports results for the full year 2018

Dec 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track

Sep 05, 2018: Kuros Biosciences announces results for first half 2018

Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer

May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM

Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results

Mar 12, 2018: Kuros Biosciences obtains European patent covering osteoinductive materials

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Kuros Biosciences AG, Performance Chart (2014-2018)

Kuros Biosciences AG, Ratio Charts

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Kuros Biosciences AG, Key Facts

Kuros Biosciences AG, Key Employees

Kuros Biosciences AG, Key Employee Biographies

Kuros Biosciences AG, Major Products and Services

Kuros Biosciences AG, History

Kuros Biosciences AG, Subsidiaries

Kuros Biosciences AG, Key Competitors

Kuros Biosciences AG, Ratios based on current share price

Kuros Biosciences AG, Annual Ratios

Kuros Biosciences AG, Annual Ratios (Cont...1)

Kuros Biosciences AG, Interim Ratios

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Kuros Biosciences AG, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Kuros Biosciences AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novartis AG

Medicopharm AG

Labatec Pharma SA

Genentech Inc

Geistlich Pharma AG

F. Hoffmann-La Roche Ltd

Aristo Pharma GmbH

Allergan Ltd